Natixis Decreases Holdings in Amedisys, Inc. (NASDAQ:AMED)

Natixis reduced its position in Amedisys, Inc. (NASDAQ:AMED - Free Report) by 83.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,895 shares of the health services provider's stock after selling 106,123 shares during the quarter. Natixis owned about 0.06% of Amedisys worth $1,897,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in AMED. Blue Trust Inc. increased its position in Amedisys by 55.1% during the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider's stock valued at $34,000 after buying an additional 124 shares in the last quarter. HBW Advisory Services LLC acquired a new position in shares of Amedisys during the fourth quarter valued at about $38,000. Versant Capital Management Inc raised its position in shares of Amedisys by 68.5% in the 4th quarter. Versant Capital Management Inc now owns 450 shares of the health services provider's stock valued at $41,000 after purchasing an additional 183 shares during the last quarter. Vestcor Inc acquired a new stake in Amedisys in the 4th quarter worth approximately $73,000. Finally, Venturi Wealth Management LLC boosted its stake in Amedisys by 397.4% in the 4th quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider's stock worth $89,000 after purchasing an additional 779 shares in the last quarter. 94.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

AMED has been the subject of a number of research analyst reports. Stephens reaffirmed an "equal weight" rating and issued a $101.00 price target on shares of Amedisys in a report on Tuesday, March 4th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $100.00 price target on shares of Amedisys in a research report on Wednesday, April 16th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, Amedisys presently has an average rating of "Hold" and an average price target of $100.75.

Amedisys Stock Up 0.7 %

NASDAQ:AMED opened at $92.43 on Wednesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. The company's fifty day moving average price is $92.12 and its 200-day moving average price is $91.83. Amedisys, Inc. has a 1-year low of $82.15 and a 1-year high of $98.95. The firm has a market capitalization of $3.03 billion, a P/E ratio of 36.68, a PEG ratio of 1.78 and a beta of 0.89.

Amedisys (NASDAQ:AMED - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share for the quarter, missing the consensus estimate of $1.05 by ($0.09). The company had revenue of $598.05 million for the quarter, compared to analyst estimates of $602.38 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. As a group, equities research analysts anticipate that Amedisys, Inc. will post 4.4 EPS for the current year.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.